Australia needs to play catch up on biomarkers

The paradigm shift from cytotoxic drugs to targeted treatments including small molecules, monoclonal antibodies and immune therapies necessitates a similar shake up in the regulation and funding of cancer biomarkers. According to a report from the University of South Australia’s Sansom Institute for Health Research, capitalising on the opportunities that come with targeted therapies has ...

Already a member?

Login to keep reading.

© 2021 the limbic